Loading…
Serum Bactericidal Activity of the Methoxyfluoroquinolones Gatifloxacin and Moxifloxacin against Clinical Isolates of Staphylococcus Species: Are the Susceptibility Breakpoints Too High?
Healthy volunteers received a single dose of gatifloxacin and moxifloxacin (400 mg each), and serum samples were obtained from these volunteers over a 24-h period. Prolonged (⩾12 h) serum bactericidal activity (SBA) was observed for both agents against staphylococcal isolates with minimum inhibitory...
Saved in:
Published in: | Clinical infectious diseases 2003-11, Vol.37 (10), p.1392-1395 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c478t-1d8630d7fe5c48c9ba3853d3d9fd8a8ec774df0f1037d2a5458666522d492ecb3 |
---|---|
cites | cdi_FETCH-LOGICAL-c478t-1d8630d7fe5c48c9ba3853d3d9fd8a8ec774df0f1037d2a5458666522d492ecb3 |
container_end_page | 1395 |
container_issue | 10 |
container_start_page | 1392 |
container_title | Clinical infectious diseases |
container_volume | 37 |
creator | Stein, Gary E. Schooley, Sharon Kaatz, Glenn W. |
description | Healthy volunteers received a single dose of gatifloxacin and moxifloxacin (400 mg each), and serum samples were obtained from these volunteers over a 24-h period. Prolonged (⩾12 h) serum bactericidal activity (SBA) was observed for both agents against staphylococcal isolates with minimum inhibitory concentrations (MICs) of gatifloxacin of ⩽0.5 µg/mL. In strains with gatifloxacin MICs of 1.0 µg/mL, SBA was observed for ⩽6 h, and, for isolates with gatifloxacin MICs of 2.0 µg/mL, little or no SBA was observed for either drug. The relative lack of SBA against less susceptible strains of staphylococci suggests that the current susceptibility breakpoint concentration (MIC, 2.0 µg/mL) for these methoxyfluoroquinolones against Staphylococcus is too high. |
doi_str_mv | 10.1086/379518 |
format | article |
fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_71316657</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4483695</jstor_id><oup_id>10.1086/379518</oup_id><sourcerecordid>4483695</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-1d8630d7fe5c48c9ba3853d3d9fd8a8ec774df0f1037d2a5458666522d492ecb3</originalsourceid><addsrcrecordid>eNqFkstuEzEUhkcIREuBJ0DILGA3YI_HY083KI0gqZQKoRSE2FiOL41bZzzYHpS8Gk-Hw0QNG8TK1jmf_3P5XRTPEXyLIGveYdoSxB4Up4hgWjakRQ_zHRJW1gyzk-JJjLcQIsQgeVycoJrkKG1Oi19LHYYNuBAy6WClVcKBiUz2p0074A1Iaw2udFr77c64wQf_Y7Cdd77TEcxEssb5rZC2A6JT4Mpv_wrcCNvFBKbOdlZm2cvonUj5XZZdJtGvd85LL-UQwbLX0up4DiZB_ym5HKLUfbIr6_aNXAQt7npvuxTBtfdgbm_W758Wj4xwUT87nGfFl48frqfzcvFpdjmdLEpZU5ZKpFiDoaJGE1kz2a4EZgQrrFqjmGBaUlorAw2CmKpKkLyapmlIVam6rbRc4bPizajb76fXMfGNzd05Jzrth8gpwig_oP8FUVvB7AE-gjL4GIM2vA92I8KOI8j3dvLRzgy-PCgOq41WR-zgXwZeHwAR845NEJ208ciRirV5-sy9Gjk_9P8u9mJkbmPy4Z6q8wdqWpLT5Zi2MentfVqEO95QTAmff_vOyWL2dTb_XHGCfwNXAM3i</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19200013</pqid></control><display><type>article</type><title>Serum Bactericidal Activity of the Methoxyfluoroquinolones Gatifloxacin and Moxifloxacin against Clinical Isolates of Staphylococcus Species: Are the Susceptibility Breakpoints Too High?</title><source>Oxford Journals Online</source><source>JSTOR</source><creator>Stein, Gary E. ; Schooley, Sharon ; Kaatz, Glenn W.</creator><creatorcontrib>Stein, Gary E. ; Schooley, Sharon ; Kaatz, Glenn W.</creatorcontrib><description>Healthy volunteers received a single dose of gatifloxacin and moxifloxacin (400 mg each), and serum samples were obtained from these volunteers over a 24-h period. Prolonged (⩾12 h) serum bactericidal activity (SBA) was observed for both agents against staphylococcal isolates with minimum inhibitory concentrations (MICs) of gatifloxacin of ⩽0.5 µg/mL. In strains with gatifloxacin MICs of 1.0 µg/mL, SBA was observed for ⩽6 h, and, for isolates with gatifloxacin MICs of 2.0 µg/mL, little or no SBA was observed for either drug. The relative lack of SBA against less susceptible strains of staphylococci suggests that the current susceptibility breakpoint concentration (MIC, 2.0 µg/mL) for these methoxyfluoroquinolones against Staphylococcus is too high.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/379518</identifier><identifier>PMID: 14583876</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Adult ; Antibacterial agents ; Antibacterials ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Aza Compounds - blood ; Aza Compounds - pharmacology ; Bacterial diseases ; Biological and medical sciences ; Blood Bactericidal Activity ; Brief Reports ; Dosage ; Drug design ; Drug Resistance, Multiple, Bacterial ; Fluoroquinolones ; Fluoroquinolones - blood ; Fluoroquinolones - pharmacology ; Human bacterial diseases ; Humans ; Infections ; Infectious diseases ; Male ; Medical sciences ; Microbial Sensitivity Tests ; Middle Aged ; Pharmacology. Drug treatments ; Quinolines - blood ; Quinolines - pharmacology ; Research studies ; Serum Bactericidal Test ; Staphylococcal infections, streptococcal infections, pneumococcal infections ; Staphylococcus ; Staphylococcus - drug effects ; Staphylococcus aureus ; Volunteerism</subject><ispartof>Clinical infectious diseases, 2003-11, Vol.37 (10), p.1392-1395</ispartof><rights>Copyright 2003 The Infectious Diseases Society of America</rights><rights>2003 by the Infectious Diseases Society of America 2003</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-1d8630d7fe5c48c9ba3853d3d9fd8a8ec774df0f1037d2a5458666522d492ecb3</citedby><cites>FETCH-LOGICAL-c478t-1d8630d7fe5c48c9ba3853d3d9fd8a8ec774df0f1037d2a5458666522d492ecb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4483695$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4483695$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,58238,58471</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15289630$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14583876$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stein, Gary E.</creatorcontrib><creatorcontrib>Schooley, Sharon</creatorcontrib><creatorcontrib>Kaatz, Glenn W.</creatorcontrib><title>Serum Bactericidal Activity of the Methoxyfluoroquinolones Gatifloxacin and Moxifloxacin against Clinical Isolates of Staphylococcus Species: Are the Susceptibility Breakpoints Too High?</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><addtitle>Clinical Infectious Diseases</addtitle><description>Healthy volunteers received a single dose of gatifloxacin and moxifloxacin (400 mg each), and serum samples were obtained from these volunteers over a 24-h period. Prolonged (⩾12 h) serum bactericidal activity (SBA) was observed for both agents against staphylococcal isolates with minimum inhibitory concentrations (MICs) of gatifloxacin of ⩽0.5 µg/mL. In strains with gatifloxacin MICs of 1.0 µg/mL, SBA was observed for ⩽6 h, and, for isolates with gatifloxacin MICs of 2.0 µg/mL, little or no SBA was observed for either drug. The relative lack of SBA against less susceptible strains of staphylococci suggests that the current susceptibility breakpoint concentration (MIC, 2.0 µg/mL) for these methoxyfluoroquinolones against Staphylococcus is too high.</description><subject>Adult</subject><subject>Antibacterial agents</subject><subject>Antibacterials</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Aza Compounds - blood</subject><subject>Aza Compounds - pharmacology</subject><subject>Bacterial diseases</subject><subject>Biological and medical sciences</subject><subject>Blood Bactericidal Activity</subject><subject>Brief Reports</subject><subject>Dosage</subject><subject>Drug design</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Fluoroquinolones</subject><subject>Fluoroquinolones - blood</subject><subject>Fluoroquinolones - pharmacology</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Quinolines - blood</subject><subject>Quinolines - pharmacology</subject><subject>Research studies</subject><subject>Serum Bactericidal Test</subject><subject>Staphylococcal infections, streptococcal infections, pneumococcal infections</subject><subject>Staphylococcus</subject><subject>Staphylococcus - drug effects</subject><subject>Staphylococcus aureus</subject><subject>Volunteerism</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqFkstuEzEUhkcIREuBJ0DILGA3YI_HY083KI0gqZQKoRSE2FiOL41bZzzYHpS8Gk-Hw0QNG8TK1jmf_3P5XRTPEXyLIGveYdoSxB4Up4hgWjakRQ_zHRJW1gyzk-JJjLcQIsQgeVycoJrkKG1Oi19LHYYNuBAy6WClVcKBiUz2p0074A1Iaw2udFr77c64wQf_Y7Cdd77TEcxEssb5rZC2A6JT4Mpv_wrcCNvFBKbOdlZm2cvonUj5XZZdJtGvd85LL-UQwbLX0up4DiZB_ym5HKLUfbIr6_aNXAQt7npvuxTBtfdgbm_W758Wj4xwUT87nGfFl48frqfzcvFpdjmdLEpZU5ZKpFiDoaJGE1kz2a4EZgQrrFqjmGBaUlorAw2CmKpKkLyapmlIVam6rbRc4bPizajb76fXMfGNzd05Jzrth8gpwig_oP8FUVvB7AE-gjL4GIM2vA92I8KOI8j3dvLRzgy-PCgOq41WR-zgXwZeHwAR845NEJ208ciRirV5-sy9Gjk_9P8u9mJkbmPy4Z6q8wdqWpLT5Zi2MentfVqEO95QTAmff_vOyWL2dTb_XHGCfwNXAM3i</recordid><startdate>20031115</startdate><enddate>20031115</enddate><creator>Stein, Gary E.</creator><creator>Schooley, Sharon</creator><creator>Kaatz, Glenn W.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>20031115</creationdate><title>Serum Bactericidal Activity of the Methoxyfluoroquinolones Gatifloxacin and Moxifloxacin against Clinical Isolates of Staphylococcus Species: Are the Susceptibility Breakpoints Too High?</title><author>Stein, Gary E. ; Schooley, Sharon ; Kaatz, Glenn W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-1d8630d7fe5c48c9ba3853d3d9fd8a8ec774df0f1037d2a5458666522d492ecb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Antibacterial agents</topic><topic>Antibacterials</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Aza Compounds - blood</topic><topic>Aza Compounds - pharmacology</topic><topic>Bacterial diseases</topic><topic>Biological and medical sciences</topic><topic>Blood Bactericidal Activity</topic><topic>Brief Reports</topic><topic>Dosage</topic><topic>Drug design</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Fluoroquinolones</topic><topic>Fluoroquinolones - blood</topic><topic>Fluoroquinolones - pharmacology</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Quinolines - blood</topic><topic>Quinolines - pharmacology</topic><topic>Research studies</topic><topic>Serum Bactericidal Test</topic><topic>Staphylococcal infections, streptococcal infections, pneumococcal infections</topic><topic>Staphylococcus</topic><topic>Staphylococcus - drug effects</topic><topic>Staphylococcus aureus</topic><topic>Volunteerism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stein, Gary E.</creatorcontrib><creatorcontrib>Schooley, Sharon</creatorcontrib><creatorcontrib>Kaatz, Glenn W.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stein, Gary E.</au><au>Schooley, Sharon</au><au>Kaatz, Glenn W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum Bactericidal Activity of the Methoxyfluoroquinolones Gatifloxacin and Moxifloxacin against Clinical Isolates of Staphylococcus Species: Are the Susceptibility Breakpoints Too High?</atitle><jtitle>Clinical infectious diseases</jtitle><stitle>Clinical Infectious Diseases</stitle><addtitle>Clinical Infectious Diseases</addtitle><date>2003-11-15</date><risdate>2003</risdate><volume>37</volume><issue>10</issue><spage>1392</spage><epage>1395</epage><pages>1392-1395</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>Healthy volunteers received a single dose of gatifloxacin and moxifloxacin (400 mg each), and serum samples were obtained from these volunteers over a 24-h period. Prolonged (⩾12 h) serum bactericidal activity (SBA) was observed for both agents against staphylococcal isolates with minimum inhibitory concentrations (MICs) of gatifloxacin of ⩽0.5 µg/mL. In strains with gatifloxacin MICs of 1.0 µg/mL, SBA was observed for ⩽6 h, and, for isolates with gatifloxacin MICs of 2.0 µg/mL, little or no SBA was observed for either drug. The relative lack of SBA against less susceptible strains of staphylococci suggests that the current susceptibility breakpoint concentration (MIC, 2.0 µg/mL) for these methoxyfluoroquinolones against Staphylococcus is too high.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>14583876</pmid><doi>10.1086/379518</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1058-4838 |
ispartof | Clinical infectious diseases, 2003-11, Vol.37 (10), p.1392-1395 |
issn | 1058-4838 1537-6591 |
language | eng |
recordid | cdi_proquest_miscellaneous_71316657 |
source | Oxford Journals Online; JSTOR |
subjects | Adult Antibacterial agents Antibacterials Antibiotics. Antiinfectious agents. Antiparasitic agents Aza Compounds - blood Aza Compounds - pharmacology Bacterial diseases Biological and medical sciences Blood Bactericidal Activity Brief Reports Dosage Drug design Drug Resistance, Multiple, Bacterial Fluoroquinolones Fluoroquinolones - blood Fluoroquinolones - pharmacology Human bacterial diseases Humans Infections Infectious diseases Male Medical sciences Microbial Sensitivity Tests Middle Aged Pharmacology. Drug treatments Quinolines - blood Quinolines - pharmacology Research studies Serum Bactericidal Test Staphylococcal infections, streptococcal infections, pneumococcal infections Staphylococcus Staphylococcus - drug effects Staphylococcus aureus Volunteerism |
title | Serum Bactericidal Activity of the Methoxyfluoroquinolones Gatifloxacin and Moxifloxacin against Clinical Isolates of Staphylococcus Species: Are the Susceptibility Breakpoints Too High? |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T00%3A33%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20Bactericidal%20Activity%20of%20the%20Methoxyfluoroquinolones%20Gatifloxacin%20and%20Moxifloxacin%20against%20Clinical%20Isolates%20of%20Staphylococcus%20Species:%20Are%20the%20Susceptibility%20Breakpoints%20Too%20High?&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Stein,%20Gary%20E.&rft.date=2003-11-15&rft.volume=37&rft.issue=10&rft.spage=1392&rft.epage=1395&rft.pages=1392-1395&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1086/379518&rft_dat=%3Cjstor_proqu%3E4483695%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c478t-1d8630d7fe5c48c9ba3853d3d9fd8a8ec774df0f1037d2a5458666522d492ecb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=19200013&rft_id=info:pmid/14583876&rft_jstor_id=4483695&rft_oup_id=10.1086/379518&rfr_iscdi=true |